TARGET study overview
A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study.
A real-world retrospective study that confirms TheraSphere for HCC as safe and effective in a select patient population, demonstrating predictable clinical outcomes across a broad patient population in 8 countries.